Skip to main content

Tecomet and Orchid Orthopedic Solutions to Merge

Global medical manufacturing combination expected to expand complementary capabilities, strengthen supply continuity and support long-term growth

Tecomet

Tecomet is a global leader in the design, development and manufacture of MedTech and Aerospace & Defense products.
Tecomet is a global leader in the design, development and manufacture of MedTech and Aerospace & Defense products.

Orchid

Orchid provides solutions for procedures in major MedTech markets in the U.S. and Europe.
Orchid provides solutions for procedures in major MedTech markets in the U.S. and Europe.

Woburn, MA, and Mason, MI, Jan. 14, 2026 (GLOBE NEWSWIRE) — Tecomet and Orchid Orthopedic Solutions (“Orchid”) today announced that they have entered into a definitive agreement to merge, bringing together highly complementary capabilities to better serve their global customers, expand reach and support long-term growth.

Tecomet is a global leader in the design, development and manufacture of MedTech and Aerospace & Defense products. Orchid provides solutions for procedures in major MedTech markets in the U.S. and Europe.

The combined company will offer an enhanced portfolio of MedTech solutions with a broader, more resilient manufacturing footprint and increased capacity to invest in advanced manufacturing, automation and capacity expansion aligned with customer demand. With the shared goal of serving customers to the highest standard, the combined joint support of both Charlesbank Capital Partners and Nordic Capital, who have been the majority owners of Tecomet and Orchid since 2017 and 2019, respectively.

Andreas S. Weller, President and CEO of Tecomet, said “We are not just merging two companies – we are committed to an integration that builds on the strengths and heritage of both Tecomet and Orchid. With complementary technologies, expanded reach and a dedicated workforce across six countries, we believe the combined company will be better positioned to advance innovation and deliver reliable, high-quality solutions for surgeons worldwide.”

Nate Folkert, CEO of Orchid, said “Strategically, this is a strong fit. By combining our manufacturing capabilities, technical expertise and global footprints, we’re creating a stronger, more competitive organization. Just as importantly, this combination is about long-term stability – building a company that is well equipped to grow, invest and create opportunity for our people.”

Until the transaction closes, Tecomet and Orchid will continue to operate as separate companies. The merger is subject to regulatory approvals and other customary closing conditions.

About Tecomet

Tecomet is a global contract manufacturer serving the medical device and aerospace & defense markets. Tecomet operates 14 manufacturing locations across five countries, offering capabilities including forging, casting, precision machining, photochemical etching, finishing, additive manufacturing and sterile packaging.

About Orchid

Orchid is a global partner to MedTech OEMs, offering manufacturing services including additive manufacturing, bone in-growth coatings, forging, casting and machining. Orchid specializes in implants, instruments, and innovative technologies within joint reconstruction, hips, knees, spine, trauma, extremities, and dental supported by 10 facilities across the U.S., the U.K., and Switzerland.

Attachments

CONTACT: Rob Sullivan
Tecomet
574-527-0443
rob.sullivan@tecomet.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.